arrow
M

Manuel Pérez-Encinas

hospital clinico universitario de santiago de compostela
H指数:26
被引数:2,042

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study
2026-09-010
OAAI
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

JAK抑制剂时代骨髓纤维化的生存结局与治疗模式

2026-08-210
PREAI
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

自体干细胞移植与强化疗巩固治疗急性髓系白血病患者的长期获益:一项来自PETHEMA AML登记研究的倾向性评分匹配分析

Leukemia
IF13.4
2025-09-010
OAAI
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

momelotinib在伴有贫血的骨髓纤维化患者中的真实世界结局:MOMGEMFIN研究的结果

2025-04-171
OA
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

自体或异基因造血干细胞移植作为成人继发性急性髓系白血病患者的首线治疗:PETHEMA登记研究经验

2025-02-010
PRE
Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

momelotinib 作为替代其他 JAK 抑制剂在贫血性骨髓纤维化患者中的真实世界疗效

BLOOD
IF23.1
2024-11-051
PRE
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

根据Ipset分层,对原发性血小板增多症患者一线羟基脲治疗反应的预后价值

BLOOD
IF23.1
2024-11-050
PRE
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study
LEUKEMIA
IF13.4
2024-10-040
PRE
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
LEUKEMIA
IF13.4
2024-09-270
PRE
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
LEUKEMIA
IF13.4
2024-08-300
PRE
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
2024-03-201
OAAI
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
2024-01-303
OAAI
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study

DNMT3A/TET2/ASXL1突变是真性红细胞增多症患者中与年龄无关的血栓形成危险因素: 一项观察性研究

2024-01-305
OAAI
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
2023-12-192
OAAI
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
2023-10-015
OAAI
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
2023-08-017
OAAI